Why the study?
Does IV landiolol provide rapid rate reduction without pronounced blood pressure drop in patients with tachycardic atrial fibrillation in an emergency setting?
Does IV landiolol provide rapid rate reduction without pronounced blood pressure drop in patients with tachycardic atrial fibrillation in an emergency setting?
Landiolol is an effective ultra-short acting IV beta-blocker for rapid rate control in tachycardic atrial fibrillation in emergency settings, with a favorable blood pressure profile.
May support IV landiolol for rapid AF rate control with stable BP; leaves open confirmation in randomized emergency trials.
This article provides new insight on landiolol, an ultra-short acting injectable betablocker, recently approved in Europe, with regard to its pharmacokinetic and pharmacodynamic profile, along with its first experience in Caucasian healthy volunteers and patients with atrial fibrillation. Landiolol as iv formulation exhibited in an emergency setting rapid rate reduction in patients with tachycardic atrial fibrillation without pronounced blood pressure drop both in caucasian and asian populations in similar manner.
No takes yet. Share an insight, caveat, or question.
Domanovits et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: